Here are Wednesday's biggest analyst calls: SpaceX, Apple, Micron, Microsoft, CoreWeave, Palantir & more

Wall Street's Wednesday analyst actions were broadly bullish, featuring multiple buy/outperform initiations and upgrades across AI infrastructure, semiconductors, healthcare, crypto-linked data centers and energy. UBS initiated CoreWeave at Buy with a $120 target implying roughly 40% upside, while Stifel upgraded Microsoft to Buy on expectations for sustained Azure upside of 200-300bps. Other notable targets included Micron at $1,300, Amazon at $320, Madrigal at $725 and Teva at $50, with analysts citing AI demand, infrastructure constraints and company-specific growth catalysts.

Analysis

The concentrated bullish coverage across AI infrastructure is more useful as a positioning signal than as new fundamental information. CRWV, APLD, CORZ, WULF, HUT and CIFR are increasingly being valued on contracted power and GPU capacity rather than legacy operating earnings; that rerating is fragile because their common bottleneck is utility interconnection and financing, not end-demand. Over the next 1-3 months, positive estimate revisions can sustain momentum, but any hyperscaler capex moderation, project-delay disclosure, or higher cost of capital would compress the entire cohort simultaneously.

The cleaner AI expression remains the platform layer: MSFT and AMZN can monetize incremental capacity through high-margin cloud, while MRVL, APH and TEL benefit from the physical scaling of clusters without taking merchant power-price or customer-concentration risk. The second-order risk is that stronger custom-silicon adoption shifts wallet share from general-purpose accelerators toward networking, optics and interconnect; MRVL/APH are therefore better hedges against compute-vendor concentration than leveraged data-center developers.

MSFT's near-term setup is more catalyst-rich than AMZN if Azure growth and AI monetization show up in reported mix and margins, but expectations now leave little tolerance for capacity deployment slippage. PLTR's government opportunity can broaden its revenue base, yet a pilot-to-production conversion timeline—not contract announcements—will determine whether its premium multiple is defensible over 6-18 months. In healthcare, HCA and GRDN offer comparatively lower-beta earnings durability, whereas BBNX, MDGL and MAZE remain primarily execution and reimbursement/regulatory-duration trades rather than broad analyst-call beneficiaries.

Contrarian view: the market may be underpricing the scarcity value of delivered, energized capacity but overpricing the ability of every announced AI data-center project to earn hyperscaler-like returns. Favor companies selling essential inputs or monetizing existing distribution over operators that must repeatedly issue equity or debt to fund speculative buildouts.

Key Decisions for Investors

• Initiate a 3-6 month pair: long MSFT / short CRWV in equal dollar terms. MSFT has diversified monetization and balance-sheet capacity; CRWV is more exposed to financing, customer concentration and buildout timing. Reassess if CRWV discloses materially improved contracted backlog economics or if Azure growth misses consensus by more than 200 bps.
• Build a basket long APH and MRVL versus a short basket of WULF, CIFR and HUT over 6-12 months. This expresses AI infrastructure growth while reducing exposure to bitcoin, power-cost and capital-raising volatility; target a 15-20% relative return, with a 10% stop on the relative spread if miners secure long-duration, investment-grade AI contracts at attractive returns.
• Hold AMZN into the next earnings print only if AWS margin expectations remain below management's implied incremental-margin trajectory; use a 3-month 10% downside put spread to protect against capex-driven free-cash-flow concerns. Trim if AWS growth fails to accelerate despite higher spending, which would challenge the capacity-monetization thesis.
• Do not chase BBNX, MDGL or MAZE solely on initiation coverage. Set alerts around reimbursement decisions, prescription-growth data and clinical/regulatory milestones; absent independently verifiable uptake, these are unsuitable substitutes for defensive healthcare exposure. Prefer HCA for a 6-18 month compounder position, with thesis invalidation on EBITDA guidance falling below its long-term growth framework.
• Treat the miner/data-center basket as a financing-spread monitor: reduce gross exposure if high-yield spreads widen by more than 75 bps, power-interconnection timelines slip, or equity issuance accelerates. Those indicators would likely lead reported earnings deterioration by one to two quarters.